Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacoeconomic issues in onychomycosis.

J Lambert1

  • 1University Hospital Antwerp, Wilrijkstraat 10, B-2650 Edegem, Antwerp, Belgium. julien.lambert@uza.be

The British Journal of Dermatology
|September 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value and Development of a Scoring System in Horses With Systemic Inflammatory Response Syndrome.

Journal of veterinary internal medicine·2017
Same author

Secukinumab: IL-17A inhibition to treat psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2017
Same author

Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.

Gut·2017
Same author

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity.

Annales de cardiologie et d'angeiologie·2016
Same author

Sedation for transfemoral aortic valve transplantation (TAVI).

Anaesthesia·2016
Same author

Diagnosis of Cutaneous T-Cell Lymphoma Detecting T-Cell Receptor γ Chain Gene Monoclonality By Denaturing Gradient Gel Electrophoresis.

Acta clinica Belgica·2016

Pharmacoeconomic studies show that combining topical amorolfine with oral terbinafine or itraconazole is a cost-effective treatment for severe onychomycosis, improving outcomes compared to oral therapy alone.

Area of Science:

  • Health economics
  • Pharmacoeconomics
  • Pharmaceuticals

Background:

  • Health economics is crucial for optimizing limited healthcare resources.
  • Pharmacoeconomics aids decision-making by evaluating treatment costs and outcomes.
  • Medical community uncertainty exists regarding pharmacoeconomic data usefulness.

Purpose of the Study:

  • To conduct pharmacoeconomic evaluations of amorolfine for severe onychomycosis.
  • To compare combination therapy with monotherapy for cost-effectiveness.

Main Methods:

  • Two pharmacoeconomic evaluations of amorolfine were performed.
  • Comparison of topical amorolfine + oral terbinafine vs. oral terbinafine alone.
  • Assessment of topical amorolfine + oral itraconazole vs. oral itraconazole alone.

Related Experiment Videos

Main Results:

  • Topical amorolfine combined with oral terbinafine improved outcomes versus oral terbinafine alone.
  • Topical amorolfine combined with oral itraconazole for 6 weeks was a cost-effective option.
  • Combination therapy for onychomycosis with amorolfine is cost-saving and effective.

Conclusions:

  • Pharmacoeconomic evaluations support combination therapy for onychomycosis.
  • Amorolfine in combination therapy offers a cost-effective strategy for treating onychomycosis.
  • Optimizing onychomycosis treatment through pharmacoeconomics demonstrates significant benefits.